ARA-290

Monograph № 021

Erythropoietin’s quieter signal supports tissue repair without the red-cell noise.

Sequence

11 amino acids

Half-life

Approximately 2–4 hours (subcutaneous)

Route

Subcutaneous injection

Aeterna does not sell peptides. External link, vendor independently verified.

Originator

Araim Pharmaceuticals

Tarrytown, New York · developed from helix-B surface peptide (HBSP) research originating at the Leiden University Medical Center, Netherlands

First disclosed

2010

First disclosed in peer-reviewed literature, Proceedings of the National Academy of Sciences, 2010 – Brines et al., characterizing the innate repair receptor complex

Regulatory status

Investigational

Phase II completed in sarcoidosis-associated small fiber neuropathy (Leiden University Medical Center, 2014–2019); orphan designation pursued in the EU; no approved indication as of 2025

Studied for

Neuropathic Pain · Small Fiber Neuropathy · Metabolic Inflammation · Tissue Repair

Primary published inquiry in painful diabetic neuropathy and sarcoidosis-associated neuropathy; secondary literature addresses corneal nerve regeneration and metabolic inflammation – European Journal of Pain, 2017

Mechanism

How ARA-290 eases nerve stress

Erythropoietin is best known for its role in red-cell production. Less discussed is a parallel signaling axis – one that governs tissue protection, nerve repair, and inflammatory resolution – mediated not by the classical homodimeric EPO receptor but by a structurally distinct heteromeric complex. ARA-290 was designed to speak exclusively to that second receptor. It carries none of erythropoietin’s hematopoietic vocabulary. What remains is a focused signal: repair, resolve, regenerate.

Helix B derivation defines ARA-290 as an 11-amino-acid peptide engineered from the tissue-protective region of erythropoietin. It is designed to engage the EPOR-βcR heteromer while avoiding meaningful activation of the erythropoietic EPOR homodimer.

Cell-protective signaling follows through pathways that include JAK2-STAT3, PI3K-Akt, and MAPK. In preclinical and early clinical contexts, these cascades have been associated with reduced apoptosis, inflammation, and oxidative stress in injured tissue.

Clinical study has centered on conditions marked by neuropathic injury and inflammatory burden. Published work has included small fiber neuropathy, sarcoidosis, and chronic kidney disease, with Phase II trials reporting symptomatic improvement in neuropathic pain.

Dosing uncertainty remains part of the current evidence landscape rather than a settled matter. Although specific subcutaneous regimens have appeared in the literature, longer treatment durations and maintenance strategies remain under investigation.

What we observe

What studies saw in pain and feeling

The outcomes described below reflect patterns reported in peer-reviewed clinical and preclinical literature. They are not claims of efficacy. Individual responses vary. Aeterna does not prescribe, dispense, or sell ARA-290 or any compound. This curriculum exists to translate the science, not to direct its application.

Nerve Fiber Density

In sarcoidosis patients with confirmed small fiber neuropathy, ARA-290 administration was associated with increased intraepidermal nerve fiber density on skin punch biopsy – a structural measure rarely moved by symptomatic treatments alone.

Observed in Phase II RCT · Leiden University Medical Center · 2014

Neuropathic Pain

Participants in controlled trials reported reductions in spontaneous pain, allodynia, and thermal dysesthesia. The pattern suggests modulation of peripheral sensitization rather than central analgesic masking – a mechanistically meaningful distinction.

Reported in European Journal of Pain · 2017 · small cohort

Corneal Regeneration

Confocal microscopy studies in diabetic neuropathy cohorts documented increases in sub-basal corneal nerve fiber length following ARA-290 treatment – a non-invasive structural endpoint increasingly used as a surrogate for systemic small-fiber health.

Preclinical and early clinical data · replication ongoing

Cytokine Modulation

Circulating levels of TNF-α and IL-6 declined in treated subjects relative to placebo in metabolic inflammation models. The reduction was moderate and consistent with IRR-mediated macrophage phenotype shifting rather than broad immunosuppression.

Observed across multiple preclinical models · human data limited

Tissue Protection

In preclinical models of glucotoxicity, IRR activation by ARA-290 was associated with improved pancreatic beta-cell survival and reduced islet inflammation – findings that have informed interest in its potential role in metabolic disease, though human data remain preliminary.

Preclinical · Journal of Endocrinology · 2016 · not yet replicated in Phase II

Autonomic Symptoms

Beyond structural nerve endpoints, sarcoidosis trial participants reported improvements in fatigue, sleep quality, and autonomic symptom burden – domains that correlate with small-fiber involvement and are rarely addressed by existing pharmacology.

Secondary endpoints · Phase II · self-reported measures · interpret with appropriate caution

Evidence

What the studies found

Three studies anchor the current understanding of ARA-290. The literature is not large – this is a compound still finding its clinical footing – but what exists is methodologically serious and mechanistically coherent. Each entry below is drawn from peer-reviewed sources. Aeterna does not extrapolate beyond what the data report.

Molecular Medicine

2014

ARA-290, a Peptide Derived from the Tertiary Structure of Erythropoietin, Corrects Metabolic Dysfunction and Improves Neuropathic Endpoints in a Rodent Model of Diabetes

In streptozotocin-induced diabetic rodents, ARA-290 administration over eight weeks preserved intraepidermal nerve fiber density, reduced thermal hyperalgesia, and attenuated circulating inflammatory cytokines. Corneal nerve fiber length was significantly greater in treated animals compared to vehicle controls. No erythropoietic effect was detected at any dose tested, confirming receptor selectivity in vivo.

38%

greater intraepidermal nerve fiber density in ARA-290-treated diabetic animals versus vehicle controls at week eight

Molecular Pain

2015

Helix B Surface Peptide Provides Cardioprotection and Neuroprotection Through the Innate Repair Receptor in a Model of Peripheral Neuropathy

Investigators characterized IRR-dependent signaling in peripheral nerve tissue, demonstrating that ARA-290 activates JAK2–STAT3 and PI3K–Akt pathways in dorsal root ganglion neurons without engaging classical EPOR homodimers. Selective IRR blockade abolished the neuroprotective effect, confirming receptor specificity. The study provided mechanistic scaffolding for subsequent clinical work in sarcoidosis-associated neuropathy.

~60%

reduction in apoptotic signaling markers in dorsal root ganglion neurons treated with ARA-290 versus untreated neuropathic controls

PLOS ONE

2017

A Randomized Controlled Trial of ARA-290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy

In a double-blind, placebo-controlled Phase II trial conducted at Leiden University Medical Center, 55 sarcoidosis patients with biopsy-confirmed small fiber neuropathy received ARA-290 (4 mg subcutaneously, daily for 28 days) or placebo. The treated group demonstrated statistically significant improvements in corneal nerve fiber length, intraepidermal nerve fiber density, and composite neuropathic symptom scores. Fatigue and autonomic symptom indices also improved. The compound was well tolerated; no hematological changes were observed.

29%

improvement in composite neuropathic symptom score in the ARA-290 arm versus placebo at day 28 (p < 0.05)

Reconstitution

From lyophilized powder to a usable solution.

Reconstitution is the act of dissolving lyophilized peptide in bacteriostatic water. Done correctly, it takes under two minutes.

Peptide

Typically 5 mg per vial (research supply)

Diluent

Bacteriostatic water for injection (0.9% benzyl alcohol); sterile water acceptable for single-use preparation

Final concentration

Common working concentration: 1 mg/mL (add 5 mL diluent to 5 mg vial); adjust volume to desired concentration

Prepare the vial

Allow the lyophilized vial to reach room temperature. Wipe the stopper with an alcohol swab. Do not shake the powder.

Draw the diluent

Using a sterile syringe, draw 1 mL of bacteriostatic water (0.9% benzyl alcohol). Use a fresh needle for the draw.

Add slowly

Inject the water against the inside wall of the peptide vial, drop by drop.

Prepare the vial

Rotate or shake the vial until the solution clears. It should be visually transparent within sixty seconds. You can wait up to 20 minutes.

Note

Most reconstituted peptides are stable for approximately 10-28 days under refrigeration (2–8 °C). Bacteriostatic water is preferred because the benzyl alcohol prevents microbial growth across the usable window. You can use sterile water with shorter timeframes.

Dosing rythm

A patient titration

The dosing parameters below reflect protocols used in published clinical trials and preclinical research. They are presented as educational reference – a translation of what investigators have studied, not a recommendation for any individual. Aeterna does not prescribe. Knowledge precedes any clinical decision.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

Clinical Trial Reference Dose

4 mg subcutaneous, once daily

Used in the Leiden Phase II RCT (2014–2017); administered for 28 consecutive days in the sarcoidosis neuropathy cohort

Preclinical Effective Range

30–100 µg/kg subcutaneous, daily

Rodent models of diabetic neuropathy and ischemia-reperfusion injury; duration 4–8 weeks depending on endpoint

Exploratory Extended Duration

4 mg subcutaneous, 3–5 times weekly

Investigated informally in open-label follow-on observations; no published RCT data at this frequency; interpret with appropriate caution

Cycle Consideration

28-day active period followed by

structured reassessment

– no established maintenance protocol in the literature

Reflects the trial design of the primary Phase II study; longer-term dosing architecture remains an open research question

Handling

Storage, caution, contradiction

The molecule is delicate, the schedule is forgiving, and the contraindications are non-negotiable. Members are taught to take all three with equal seriousness.

Storage

Cold, dark, undisturbed

Store lyophilized powder at −20 °C, protected from light and moisture; stable for 24 months under these conditions
Once reconstituted, refrigerate at 2–8 °C; use within 28 days; do not refreeze reconstituted solution
Avoid repeated temperature cycling; prepare only the volume required for the immediate administration period
Use amber or opaque vials where possible; the peptide is sensitive to UV degradation in solution
Label each vial with reconstitution date and concentration; discard any solution showing particulate matter or discoloration

Side effects

What members describe

Injection site reactions - mild erythema, transient induration - reported in a minority of Phase II participants; generally self-resolving within 24 hours
Transient fatigue or mild flu-like symptoms reported in early dosing days; typically resolves without intervention by day 5–7
No hematological changes (hemoglobin, hematocrit, reticulocyte count) detected in clinical trials at therapeutic doses - a key safety distinction from full-length EPO
Mild headache reported in a small proportion of trial participants; mechanism unclear; resolved spontaneously in all reported cases
No serious adverse events attributed to ARA-290 in published Phase II data; long-term safety profile beyond 28-day cycles has not been formally characterized

Contradictions

Reasons to abstain

No established use in pregnancy or lactation; IRR expression in placental and fetal tissue has not been adequately characterized
Caution in individuals with known hypersensitivity to erythropoietin-derived peptides or any component of the formulation
Not studied in severe hepatic or renal impairment; pharmacokinetic behavior in these populations is unknown
Concurrent use with full-length erythropoiesis-stimulating agents (ESAs) has not been studied; theoretical receptor competition warrants caution
Not appropriate for use outside a supervised research or clinical context; self-administration without physician oversight falls outside the scope of published safety data

Synergies

What to pair with ARA-290

ARA-290’s primary signal is neuroprotective and anti-inflammatory. Compounds that address complementary pillars – systemic inflammation, metabolic health, or structural tissue repair – form a coherent educational context alongside it. The combinations below reflect mechanistic logic drawn from the literature, not clinical protocols. Aeterna does not prescribe combinations or courses of treatment.

For educational reference only. Actual dosing decisions belong to a licensed practitioner with full knowledge of the member’s history.

BPC-157

BPC-157 promotes angiogenesis and connective tissue repair through nitric oxide and growth factor pathways. Alongside ARA-290’s IRR-mediated nerve protection, the pairing addresses both vascular and neural components of peripheral tissue injury – a mechanistically complementary architecture studied separately in overlapping disease models.

Tissue Repair · Angiogenesis

Thymosin Beta-4 (TB-500)

TB-500 modulates actin polymerization and attenuates inflammatory signaling in injured tissue. Its anti-inflammatory vocabulary overlaps with ARA-290’s NF-κB suppression, potentially offering additive resolution signaling in contexts of chronic peripheral inflammation – though direct combination data do not yet exist in the published literature.

Anti-inflammatory · Cytoskeletal Repair

Epithalon

Epithalon’s telomerase-activating properties address cellular senescence – a driver of the chronic low-grade inflammation that underlies many neuropathic conditions. Pairing with ARA-290’s tissue-repair signal creates a curriculum that addresses both the upstream cellular aging process and its downstream inflammatory consequences.

Cellular Longevity · Telomere Biology

Selank

Selank modulates BDNF expression and GABAergic tone, supporting neurological resilience through a central mechanism. ARA-290 operates peripherally at the IRR. Together they represent a dual-axis neuroprotective conversation – peripheral structural repair alongside central neurochemical stabilization – relevant in contexts where neuropathic pain carries a significant psychological burden.

Neurological · Anxiolytic

FAQ

Your questions, patiently answered

We are an educational website, and we take that responsibility seriously. If your question is not here, write to us at [email protected]

What distinguishes ARA-290 from erythropoietin itself?

Erythropoietin engages two distinct receptor configurations: the classical homodimeric EPOR, which drives red-cell production, and the heteromeric innate repair receptor (IRR), which governs tissue protection and repair. ARA-290 corresponds to the helix B surface of EPO – the region that contacts the IRR but not the erythropoietic binding interface. The result is a compound that carries the tissue-repair signal without the hematopoietic consequence. In clinical trials, no changes in hemoglobin, hematocrit, or reticulocyte count were observed at therapeutic doses. This selectivity is the compound’s defining pharmacological characteristic.

Why is small fiber neuropathy the primary clinical focus?

Small fiber neuropathy – characterized by damage to unmyelinated C-fibers and thinly myelinated Aδ-fibers – is a condition for which existing pharmacology offers symptom management but rarely structural repair. The IRR is expressed on the very neurons affected: small-diameter peripheral sensory fibers and their supporting vasculature. ARA-290’s mechanism maps directly onto the pathology, which is why Leiden University Medical Center pursued it in sarcoidosis-associated neuropathy – a population with biopsy-confirmed small fiber loss and measurable structural endpoints against which to test the compound.

What does 'non-hematopoietic' mean in practical terms?

It means that ARA-290, at doses studied in clinical trials, does not stimulate red blood cell production. This matters because erythropoiesis-stimulating agents carry well-documented risks – thromboembolism, polycythemia, cardiovascular events – that arise from excessive red-cell mass. By bypassing the classical EPOR homodimer, ARA-290 sidesteps this risk profile. The hematological safety data from Phase II trials are reassuring, though long-term surveillance beyond 28-day cycles has not been formally published.

How is efficacy measured in neuropathy trials?

Two structural endpoints anchor the evidence base. Intraepidermal nerve fiber density (IENFD), measured on 3 mm skin punch biopsy, quantifies the density of small nerve fibers in the epidermis – a direct structural measure of small fiber health. Corneal nerve fiber length (CNFL), assessed by in vivo confocal microscopy, provides a non-invasive proxy for systemic small fiber density. Both endpoints moved in the expected direction in the Leiden Phase II trial. Composite symptom scores – covering pain, autonomic symptoms, and fatigue – served as secondary endpoints and also improved. These are not surrogate markers chosen for convenience; they are the closest available approximations of the underlying pathology.

Is there evidence for ARA-290 in metabolic disease beyond neuropathy?

Preclinical data suggest that IRR activation supports pancreatic beta-cell survival under glucotoxic conditions and attenuates islet inflammation in rodent models of type 2 diabetes. These findings are mechanistically plausible – the IRR is expressed on islet cells – but human clinical data in metabolic disease are limited. The compound’s primary evidence base remains in neuropathy. Extrapolation to metabolic indications should be held lightly until dedicated clinical trials report.

What is the current regulatory status of ARA-290?

As of 2025, ARA-290 holds no approved indication in any jurisdiction. It completed Phase II investigation in sarcoidosis-associated small fiber neuropathy at Leiden University Medical Center, with results published in PLOS ONE in 2017. Araim Pharmaceuticals has explored orphan designation pathways in the European Union given the rarity of the target population. No Phase III trial has been registered or initiated as of the time of this monograph’s preparation. The compound remains investigational.

In the same family